Jefferies Group reiterated their buy rating on shares of Zoetis (NYSE:ZTS) in a report issued on Tuesday. Jefferies Group currently has a $89.00 price objective on the stock. Jefferies Group also issued estimates for Zoetis’ FY2017 earnings at $2.38 EPS, FY2018 earnings at $3.11 EPS, FY2019 earnings at $3.59 EPS, FY2020 earnings at $4.06 EPS, FY2021 earnings at $4.47 EPS and FY2022 earnings at $4.93 EPS.
Several other equities analysts have also recently weighed in on the company. Morgan Stanley upgraded Zoetis from an equal weight rating to an overweight rating and set a $80.00 price objective on the stock in a research note on Wednesday, November 29th. Zacks Investment Research cut Zoetis from a buy rating to a hold rating in a research note on Wednesday, November 1st. BidaskClub upgraded Zoetis from a sell rating to a hold rating in a research note on Friday, October 13th. Cantor Fitzgerald set a $80.00 price objective on Zoetis and gave the company a buy rating in a research note on Tuesday, December 12th. Finally, Stifel Nicolaus restated a buy rating and set a $65.00 price objective on shares of Zoetis in a research note on Tuesday, October 24th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have assigned a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $73.72.
Zoetis (NYSE ZTS) opened at $76.62 on Tuesday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80. Zoetis has a 52 week low of $52.00 and a 52 week high of $77.03. The firm has a market capitalization of $37,194.72, a price-to-earnings ratio of 35.01, a price-to-earnings-growth ratio of 1.83 and a beta of 1.06.
Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.02. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.32 billion. During the same period last year, the business earned $0.52 EPS. The business’s revenue was up 8.5% on a year-over-year basis. equities research analysts anticipate that Zoetis will post 2.36 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, January 19th will be paid a $0.126 dividend. This is a boost from Zoetis’s previous quarterly dividend of $0.11. This represents a $0.50 dividend on an annualized basis and a yield of 0.66%. The ex-dividend date is Thursday, January 18th. Zoetis’s payout ratio is currently 26.32%.
A number of hedge funds have recently bought and sold shares of the business. Wilbanks Smith & Thomas Asset Management LLC grew its holdings in Zoetis by 1.8% during the 2nd quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 5,682 shares of the company’s stock valued at $354,000 after buying an additional 98 shares in the last quarter. Scotia Capital Inc. grew its holdings in Zoetis by 1.5% during the 2nd quarter. Scotia Capital Inc. now owns 9,628 shares of the company’s stock valued at $601,000 after buying an additional 142 shares in the last quarter. Nordea Investment Management AB grew its holdings in Zoetis by 0.7% during the 2nd quarter. Nordea Investment Management AB now owns 24,854 shares of the company’s stock valued at $1,550,000 after buying an additional 169 shares in the last quarter. Moors & Cabot Inc. grew its holdings in Zoetis by 1.1% during the 2nd quarter. Moors & Cabot Inc. now owns 14,969 shares of the company’s stock valued at $929,000 after buying an additional 170 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in Zoetis by 16.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after buying an additional 230 shares in the last quarter. 93.14% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Jefferies Group Reiterates Buy Rating for Zoetis (ZTS)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/20/jefferies-group-reiterates-buy-rating-for-zoetis-zts.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.